Ceva posts strong double-digit organic growth once again in first half of 2016 >
Consolidated sales of the Ceva Group reached €455m at the end of June 2016.
Ceva acquires Biovac >
Move will reinforce group’s AMR strategy to find alternative solutions to use of antibiotics.
Ceva Posts Strong Double-Digit growth again in 2014 >
Consolidated sales of the Ceva Group reached €766m at the end of 2014, representing growth of 23% and +14.1% at a constant perimeter and exchange rates.
Another investment of HUF 2 billion from Ceva-Phylaxia >
Ceva-Phylaxia, one of the veterinary market leaders expands its vaccine production plant again.
50 billionth domestic poultry vaccine reaches completion >
As a market leader, the so-called immune complex vaccines against one of the most frequent catching disease that affects chickens are produced in Hungary.
Press Release: The new canine disease can be prevented >
Press Release: The big tick map is to come >
Ceva records double digit growth for 3rd. successive year >
14% growth pushes sales beyond 600 M€ for first time
Innovation drives Ceva's growth >
You can find in the attachment the mid-year result 2012 of the Ceva Group